Capsaicin 8% patch repeat treatment in non-diabetic peripheral neuropathic pain: a 52-week, open-label, single-arm, safety study

Rafael Gálvez, MDa Marie-Louise Navez, MDb Graeme Moyle, MDc Christian Maihöfner, MDb Malcolm Stoker, PhDc Etienne Ernault, MSc Turo J. Nurmikko, MD, PhDb Nadine Attal, MD, PhD¢

aUnidad del Dolor, Hospital Universitario Virgen de las Nieves, Granada, Spain. bCentre Stéphanois de la douleur, Saint Etienne, France. cChelsea & Westminster NHS Foundation Trust, London, UK. dDepartment of Neurology, General Hospital Fürth, Fürth, Germany. eAstellas Pharma Europe B.V., Leiden, The Netherlands. fThe Walton Centre NHS Foundation Trust, University of Liverpool, Clinical Sciences Centre, Liverpool, UK. ¢Centre d'évaluation et de Traitement de la Douleur and INSERM U 987, Hôpital Ambroise Paré, Boulogne-Billancourt, France.

Corresponding author: Dr Rafael Gálvez, Unidad del Dolor, Hospital Universitario Virgen de las Nieves, Avda. de las Fuerzas Armadas 2, 18014 Granada, Spain

Email: rafaelgalvez@hotmail.com; Tel: +34 95 824 1508; Fax: +34 95 824 1245
Conflicts of Interest and Source of Funding

This study was funded by Astellas Pharma Europe B.V., Leiden, The Netherlands. Astellas Pharma Europe B.V. developed the protocol in conjunction with the clinical investigators and provided the study drug. The STRIDE study was initiated and funded by Astellas Pharma Europe B.V. Turo J. Nurmiotto has acted as a consultant to Astellas Pharma. Nadine Attal has received honoraria from Pfizer, Lilly, Grünenthal, Astellas Pharma, Johnson and Johnson, Sanofi Pasteur Mérier et Adir for advisory boards, scientific advice or speakers bureau. Christian Maihöfner has received honoraria as consultant for Astellas, Bionorica and Mundipharma and has participated in speakers bureaus of Allergan, Astellas Pharma, Grünenthal, Janssen, and Pfizer. Graeme Moyle and Marie-Louise Nave have no disclosures. Rafael Galvez has received honoraria from Grünenthal, Mundipharma and Eisai Co, Ltd. for speakers’ bureau. Malcolm Stoker and Etienne Ernault are employed by Astellas Pharma Europe B.V. The authors received editorial support for manuscript preparation from Vicky Hintridge, Quercus Medical Communications Ltd, and this assistance was supported by Astellas Pharma Europe Ltd. The authors, however, directed and are fully responsible for all content and editorial decisions for this manuscript.

Acknowledgements

Rafael Gálvez, MD, was the Coordinating Investigator of this study. The authors would like to thank all study investigators (for full list see Supplementary Table 1, Supplemental Digital Content 1, http://links.lww.com/CJP/A396) and Faysal Riaz of Astellas Pharma Europe Ltd., Chertsey, UK, for critical review and his valuable medical writing assistance.

Abstract

Objectives: To investigate long-term safety and tolerability of capsaicin 8% patch repeat treatment in non-diabetic patients with peripheral neuropathic pain (NP).

Methods: Prospective, open-label, observational study in patients with post-herpetic neuralgia, post-traumatic or post-surgical nerve injury, HIV-associated distal sensory polyneuropathy, or other peripheral NP, and average daily pain score ≥4, received ≤6 capsaicin 8% patch treatments over 52 weeks according
to clinical need (retreatment at 9–12 week intervals). Sensory testing and analgesic effectiveness were assessed using ‘bedside tests’ and Brief Pain Inventory (question 5).

**Results:** Overall, 306 patients received treatment. Treatment-emergent adverse events (TEAE) and drug-related TEAEs were reported by 252 (82.4%) and 207 (67.6%) patients. Application site pain was the most common drug-related TEAE (n=112, 36.6%); no drug-related serious TEAEs were reported. Sensory category shift analyses from baseline to end of study (EoS) in patients attending at least two sensory visits (n=278 for all tests except warm, n=277) found sensory deterioration/loss in at least one modality in 50.4% (n=140); deterioration/loss in one, two, three, four or five modalities occurred in 26.6% (n=74), 14.0% (n=39), 5.8% (n=16), 2.5% (n=7) and 1.4% (n=4). Newly emergent hyperaesthesia or allodynia was apparent in 1.1–3.6% (depending on modality) by EoS. Between 25.2 and 32.0% of patients reported improvement in a sensory modality by EoS. Average daily pain was 6.6 and 4.7 at baseline and Month 12.

**Conclusions:** Generally, capsaicin 8% patch repeat treatment over 52 weeks was well tolerated, with variable alteration in sensory function and minimal chance of complete sensory loss.

ClinicalTrials.gov Identifier: NCT01252160

Word count: 250 (Max = 250)

**Key words:** Capsaicin 8% patch; peripheral neuropathic pain; safety; sensory function; Phase 3 study. [Max = 5 words]

**Introduction**

Neuropathic pain (NP) is a common neurological condition with an estimated prevalence of 6.9–8.2% among the general population in Europe, imposing a significant burden on healthcare organisations.\textsuperscript{1,2} The condition has been associated with a lower overall health-related quality of life in patients, in particular
impairment of physical, emotional and social functioning as well as sleep quality. In clinical practice the management of NP remains suboptimal and challenging, often resulting in chronic disease. A large proportion of patients with NP still receive inadequate pain relief, despite the availability of a substantial number of treatments. Frequently used treatments for NP, such as antidepressant, anticonvulsant and opioid medications, act on the central nervous system and are associated with a number of limitations in routine clinical practice. These include lengthy dose titration, numerous drug-drug interactions, serious adverse events, reduced compliance with treatment due to adverse events, the need for multiple daily dosing, potential for abuse and unclear responder criteria.

Capsaicin is a potent, highly selective vanilloid receptor subtype 1 (TRPV1) agonist that causes depolarisation of sensory afferents, inducing short-lived warming, burning, stinging or itching sensations. Exogenous agonists of TRPV1, such as capsaicin, are able to prolong this depolarisation, causing defunctionalisation of hyperactive nociceptors in the skin, leading to pain relief. The capsaicin 8% patch delivers a high concentration of capsaicin directly into the skin to provide both acute and long-lasting pain relief. In addition, minimal significant systemic absorption limits the potential for drug-drug interactions or the need for dose adjustment in the elderly or patients with hepatic or renal impairment.

Several prospective, double-blind studies have confirmed the safety and efficacy of the capsaicin 8% patch in post-herpetic neuralgia (PHN) and painful HIV-related neuropathies. Results from a large, open-label study in various localised peripheral PNP aetiologies also demonstrated that the capsaicin 8% patch was well tolerated. A further study demonstrated non-inferior efficacy versus pregabalin, a first-line treatment for NP. More recently, clinical studies were conducted in patients with painful diabetic peripheral neuropathy, which subsequently led to an expansion of the European indication for the capsaicin 8% patch to the treatment of peripheral NP in adults either alone or in combination with other medicinal products for pain.
In healthy subjects, the safety of single and repeated capsaicin 8% patch treatments has been established using neurological examination, quantitative sensory testing and skin punch biopsies. The primary objective of the present prospective study was to investigate for the first time the long-term safety and tolerability of capsaicin 8% patch repeat treatment over 52 weeks in non-diabetic patients with a broad range of peripheral NP aetiologies. Of particular interest in this study was the potential for any clinically relevant deficit in sensory perception or increase in hypersensitivity following repeated application of capsaicin. Analgesic effectiveness was assessed as a secondary outcome. The objective of this study was to mimic capsaicin 8% patch treatment in clinical practice as far as possible.

**Methods**

**Patients**

This phase IV, open-label, single-arm, 52-week, observational study (ClinicalTrials.gov Identifier: NCT01252160) was conducted at 63 sites in Europe between October 2010 and September 2013.

Key inclusion criteria included: age between 18 and 90 years with a diagnosis of PHN (pain persisting since shingles vesicle crusting), post-traumatic or post-surgical nerve injury ([PNI]), HIV-associated distal sensory polyneuropathy (HIV-DSPN) (confirmed using the Brief Peripheral Neuropathy Screen), all of a minimum duration of 3 months, or other adequately characterised peripheral NP, including idiopathic small fiber neuropathy (ISFN) (based on clinical criteria or skin biopsy, with loss of pinprick and temperature sensation in both feet); an average daily pain score ≥4 on the question 5 of the Brief Pain Inventory (BPI); intact, non-irritated, dry skin over the painful area to be treated; and in good health as determined by the investigator.

Key exclusion criteria included: any prior use of capsaicin patches; past or current history of type I or type II diabetes mellitus; use of oral or transdermal opioids exceeding a total daily dose of morphine of 80 mg/day, or equivalent, or any parenteral opioids, regardless of dose, within 7 days preceding the first
patch application visit; use of any topical pain medication within 7 days preceding the first patch
application visit; unstable or poorly controlled hypertension, or a recent history of a cardiovascular event;
clinically significant abnormal electrocardiogram; significant ongoing or untreated abnormalities in
cardiac, renal, hepatic or pulmonary function; significant pain of an aetiology other than painful HIV-
DSPN, PHN, PNI, ISFN, or other adequately characterised peripheral NP; Complex Regional Pain
Syndrome (type I); neuropathic pain areas located only on the face, above the hairline of the scalp, and/or
in proximity to mucous membranes.

The study was approved by the institutional review board at each participating site, and was conducted in
accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice, International
Conference on Harmonization guidelines, and applicable laws and regulations. Written, informed consent
was obtained from all patients prior to initiating study-related procedures.

Study treatment

Patients received up to six capsaicin 640 g/cm² (8% weight for weight) patch treatments (QUTENZA™
cutaneous patch (capsaicin 179 mg patch [8% w/w]), supplied by Astellas Pharma Europe Ltd., Chertsey,
UK) at 9–12 week intervals over a 52-week period. At each application visit, a maximum of four patches
equivalent to an area of up to 1120 cm² were applied for 30 minutes to the feet or 60 minutes to other
body locations. Prior to patch application, patients received pre-treatment with a topical local anaesthetic,
the choice of which was at the investigator’s discretion. At screening and each application visit the
treatment area was demarcated, which included assessment of the most painful area and the area of
alldynia/hyperalgesia. If alldynia was present, then the most painful area plus any additional area(s) of
alldynia beyond the most painful area were treated up to a maximum of 1120 cm², with highest priority
for patch use given to treating the most painful area. Capsaicin 8% patch retreatment took place
depending on investigator discretion and patient feedback. Patients who did not attend a further patch
retreatment visit prior to Week 26 were recalled to determine if a further retreatment was required.
Assessments

Safety and tolerability

The primary objective of the study was to assess the long-term safety and tolerability, after repeated treatment, of the capsaicin 8% patch over a 52-week period. A treatment-emergent adverse event (TEAE) was defined as an adverse event observed after the start of capsaicin 8% patch application, or an adverse event which worsened in severity after patch application. A serious TEAE was any untoward medical occurrence that resulted in death, persistent or significant disability/incapacity, congenital anomaly, or birth defect, in-patient hospitalisation, led to prolongation of hospitalisation, was life threatening or considered a medically important event.

Sensory examination was performed to identify clinically relevant deficits in sensory function at baseline and before each capsaicin 8% patch treatment. Testing was performed at the screening visit, at all patch application visits (prior to patch application), at Week 26 (if applicable), and at the planned (Weeks 52–65) or early termination visit, by physicians who had been given study training. Sensory perception was assessed using standardised ‘bedside tests’ of response to light brush, pinprick, vibration, warm and cold (see protocol in Supplementary Text 1, Supplemental Digital Content 2, http://links.lww.com/CJP/A397). The examining physician was advised to test up to five locations within the affected area. For each sensory modality, except cold, a single scale was used that ranged from loss of sensation to increased sensitivity: not felt, barely felt, normally felt, increased and not paraesthetic/dysaesthetic, increased and paraesthetic/dysaesthetic, increased and painful. For perception of cold the categories used were: not cold, slightly cold, normally cold, cold but not paraesthetic/dysaesthetic, cold and paraesthetic/dysaesthetic, increased and painful. An unaffected mirror-image area, on the other side (PHN), or anterior thigh or upper forearm (HIV-AN), or other area, as appropriate, was used as a demonstration site. In addition, reflex testing involved assessment of the Achilles tendon reflex using the rating scale: no response, hypoaactive, normal, hyperactive, clonus. The physician then chose one response that they considered to
be most clinically relevant. The sensory categories reported at baseline and study end were recorded for each patient and a category shift schema was developed to ascertain if a patient improved, had no change or experienced loss in sensory function during the study.

The areas of spontaneous pain and allodynia/hyperalgesia were also measured at each visit as part of the sensory examination. The composite term allodynia/hyperalgesia was used to describe presence of dynamic mechanical allodynia, cold allodynia (or hyperalgesia), heat allodynia (or hyperalgesia) and pinprick hyperalgesia. The area of allodynia/hyperalgesia and the most painful area were identified by patients, and mapped by the physician. Mapping of both was performed using a cotton swab to gently stroke the skin from outside the usual most painful or sensitive area(s) towards the centre, from six to eight directions (from above, below, left, right, etc.). The boundary was marked at the exact location where a light swab stroke became painful (if applicable), traced on a piece of tracing paper or plastic transparency film, and the area calculated.

**Analgesic effectiveness**

Assessment of analgesic effectiveness was a secondary endpoint in this study. Assessments included average daily pain (BPI question 5) and Patient Global Impression of Change (PGIC).

The BPI Modified Short Form is a widely used and validated, patient-completed, numeric rating scale that measures severity of pain and its interference with daily function. Average daily pain was rated using a 0 to 10 numeric scale anchored at zero for “no pain” and 10 for “pain as bad as you can imagine” for severity. Average pain was recorded daily during screening and weekly from the first patch application visit until the planned or early termination visit. All responses were recorded on the same day of the week (± 2 days), as chosen by the patient during the first patch application visit.

The PGIC is a patient-rated instrument that measures changes in the overall status of patients on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Patients answered a PGIC questionnaire at patch application visits (except first patch application visit), 4 weeks after each patch.
application visit, at Week 26 (if applicable), and at the planned or early termination visit. The EQ-5D visual analogue scale (VAS) score was also assessed at baseline and at the planned or early termination visit.

**Statistical analyses**

It was planned to enroll 300 eligible patients in the study. The sample size was based on clinical judgment to adequately assess the safety of repeated treatments of capsaicin 8% patch over 1 year. A sample size of 300 patients gave a 95% chance of observing at least one patient with an event with an incidence of 1%. The safety analysis set included all patients who received at least one capsaicin 8% patch and was used for all analyses of safety and effectiveness.

Descriptive statistics were used to describe the absolute values and changes from baseline for “pain now” scores, PGIC and areas of pain and allodynia. Summary statistics for change from baseline in average daily pain was also performed.

Post-hoc analyses of sensory and reflex testing were performed in patients who received three consecutive treatments and post-hoc analyses of pain scores, PGIC and EQ-5D were performed in patients who received four consecutive treatments. To assess variability in the change in pain scores among diagnostic groups, a post-hoc analysis was performed to calculate 95% CI for changes from baseline to Month 12.

A detailed post-hoc analysis was carried out for each sensory modality to identify any shift in the sensory category from baseline. Based on the mode of action of the capsaicin 8% patch and previous studies, it was assumed that two types of shift in the sensation of the treated skin area could occur: deterioration/loss of sensory acuity or increased sensitivity. Deterioration/loss of sensation was considered to have occurred if the sensory category moved from increased sensitivity or normal sensation to “barely felt” (“slightly cold”) or “not felt” (“not cold”), or from “barely felt” (“slightly cold”) to “not felt” (“not cold”) after treatment (Supplementary Table 2a, Supplemental Digital Content 3, http://links.lww.com/CJP/A398). If a patient shifted to the category “increased sensitivity and pain” by study end, they were considered to
have developed new hyperaesthesia/allodynia (Supplementary Table 2b, Supplemental Digital Content 3, http://links.lww.com/CJP/A398). However, if a patient with increased or inadequate sensation moved to “normal” or another improved category according to Supplementary Table 2c, Supplemental Digital Content 3, http://links.lww.com/CJP/A398 by study end, they were considered to have improvement of sensation. Patients who reported the same sensory category at baseline and study end were classified into the “no change” group. A total of four possible category shifts did not fit into the above categories and were designated “unclear change” (Supplementary Table 2d, Supplemental Digital Content 3, http://links.lww.com/CJP/A398).

Results

Patients

A total of 345 patients were screened and 306 patients received capsaicin 8% patch treatment, of whom 107 had a diagnosis of PHN, 99 had PNI, 80 had HIV-DSPN and 20 other peripheral NPs.

At baseline in the total population, the mean (standard deviation [SD]) age was 57.9 [15.0] years, average time since peripheral NP diagnosis 5.1 [5.5] years, and average daily pain score 6.6 [1.4] (Table 1). Baseline average pain scores in each diagnostic group were: PHN, 6.6 [1.5]; PNI, 6.8 [1.4]; HIV-DSPN, 6.4 [1.5]; other peripheral NP, 6.7 [1.2]. Other demographic and baseline characteristics such as age, time since diagnosis and ethnicity were similar between the pain diagnostic groups (Table 1).

Except for one patient in the PHN group, all patients used pre-application topical anaesthetics during the study (n=305; 99.7%): amides were the most frequent chemical subgroup (n=291; 95.1%). All patients used concomitant pain therapy during the study, and the most frequent medications used for neuropathic pain are summarised in Table 2 (Overall 77.8%, PHN, 79.4%; PNI, 83.8%; HIV-DSPN, 65.0%; other peripheral NP, 90.0%). Post-application medications (administered on days 1 to 5 after patch application) were used by 37.6% of patients (PHN, 43.9%; PNI, 38.4%; HIV-DSPN, 31.3%; other peripheral NP, 25.0%).
Overall, 176 patients (57.5%) completed the study after receiving treatment (Figure 1). In total, 130 patients (42.5%) discontinued after treatment was initiated, most commonly due to lack of effectiveness (n=54; 17.6%), withdrawal by patient (n=33; 10.8%) and loss to follow up (n=17; 5.6%). The average interval between each capsaicin 8% patch retreatment was 107.0 days. The majority of patients received only one capsaicin 8% patch treatment (n=76; 24.8%) in this study, and the proportion of patients subsequently receiving further capsaicin treatments steadily decreased throughout the duration of the study (Figure 2a). In total, 52% (159/306) of patients received three capsaicin 8% patch treatments and 32.7% (100/306) received four treatments during the study (Figure 2b). When analysed by study visit, the proportion of patients who discontinued decreased throughout the study and the proportion of completers increased (Supplementary Figure 1, Supplemental Digital Content 4, http://links.lww.com/CJP/A399; ad-hoc analysis).

**Safety and tolerability**

**TEAEs**

A total of 252 patients (82.4%) reported a TEAE and the proportions were similar between the diagnostic groups (Table 3). The maximum reported severity was mild for 78 patients (25.5%), moderate for 104 patients (34.0%) and severe for 70 patients (22.9%), which corresponded to 142 reported severe TEAEs (Table 3). The most commonly reported TEAE was application site pain (36.6%). An increase in blood pressure that was considered by the study investigator to be unusual for the patient, or that required further intervention, was observed in 7 patients (2.3%). Eleven patients (3.6%) discontinued treatment due to TEAEs (reported only once); five from the PHN group (application site erythema, application site pain, and PHN in one patient, and cerebral haemorrhage, facial neuralgia, pain, squamous cell carcinoma in the other four patients); four from PNI group (burning sensation, complex regional pain syndrome, neuralgia, renal colic); one from HIV-DSPN group (pneumonia); and one from other peripheral NP group (allodynia). Three deaths occurred during the study period and none were considered to be related to
study treatment, as assessed by the study investigator. Two deaths occurred in the PHN group (cerebral haemorrhage and squamous cell carcinoma) and one in the HIV-DSPN group (pneumonia).

**Drug-related TEAEs**

Drug-related TEAEs were reported by 207 patients (67.6%) (Table 3). The maximum reported severity was mild for 84 patients (27.5%), moderate for 82 patients (26.8%) and severe for 41 patients (13.4%). Application site pain (22/306 patients; 7.2%) was the most common severe drug-related TEAE, reported by ≥5% patients in all diagnostic groups. Three patients (1.0%) discontinued due to drug-related TEAEs: one patient in PHN group (application site erythema, application site pain and PHN); one patient in PNI group (neuralgia); and one patient in other peripheral NP group (allodynia). The proportion of patients who experienced drug-related TEAEs did not change over the course of the study (130/230 [56.5%] patients between first and second treatment; 87/159 [54.7%] between second and third; 57/100 [57.0%] between third and fourth; 26/52 [50.0%] between fourth and fifth treatment; 7/16 [43.8%] between fifth and sixth).

**Sensory perception and reflex testing**

In the total population, sensory category shift analyses in patients who attended at least two sensory testing visits (n=278 for all tests except warm, n=277), found that 50.4% (n=140) reported sensory deterioration/loss in at least one modality by study end versus baseline. The number of patients with deterioration/loss in one, two, three or four tests by study end was 26.6% (n=74), 14.0% (n=39), 5.8% (n=16) and 2.5% (n=7), respectively. A total of four patients had sensory deterioration/loss in all five sensory tests by study end versus baseline. The diagnostic groups and most painful areas were as follows: PHN, n=1 (torso); HIV-DSPN, n=1 (legs); PNI, n=2, (feet, arms). In these four patients, sensory deterioration/loss occurred at treatments one, two, six and end of study, respectively.

At study end, 40.7–49.3% (depending on test) of patients showed no sensory change compared with baseline, and 25.2%–32.0% (depending on test) reported an improved sensory category by study end.
Between 1.1% and 3.6% of patients (depending on the test) reported new hyperesthesia/allodynia at study end. With regards to reflex testing, an improved response was observed in 11.3% of patients by study end compared with baseline.

Analysis of pain in patients with sensory deterioration/loss and improvement (according to scheme in Supplementary Table 1, Supplemental Digital Content 1, http://links.lww.com/CJP/A396) in the total population by study end, found mean changes in average pain from baseline to EoS ranged from -1.2 to -1.6 (depending on test) in patients who reported deterioration/loss of sensory perception, and from -1.3 to -2.2 in patients who reported an improvement in sensory perception. In addition, analysis of quality of life changes from baseline to end of study found mean changes in EQ-5D VAS score ranged from -2.0 to 5.4 in patients who reported a deterioration/loss of sensory perception, and -2.8 to 8.8 in patients who reported improved sensory perception.

Following three consecutive capsaicin 8% treatments (n=100 for all tests except warm, n=99), the majority of patients either showed no sensory change (41.0–48.0% depending on test) or actual improvement (28.0%–37.0%) before fourth treatment (Table 5). Sensory category shift analyses from baseline found that 50.0% of patients (n=50) reported sensory deterioration/loss in at least one modality by study end versus baseline, while the number of patients with sensory deterioration/loss in one, two, three, four or five tests was 23.0% (n=23), 20.0% (n=20), 3.0% (n=3), 2.0% (n=2), and 2.0% (n=2), respectively.

**Area of allodynia/hyperalgesia**

In the total population, the mean [SD] area of allodynia/hyperalgesia decreased from 241.9 cm² [259.1] (interquartile range [IQR]: 62.5–323.5) before first application (n=224) to 219.9 cm² [286.7] (IQR: 36.0–282.0) at end of study (n=245). In patients with PHN, the area decreased from 251.1 cm² [219.5] (IQR: 106.0–323.5) before first application (n=96) to 192.3 cm² [212.8] (IQR: 37.0–255.0) at end of study (n=105).
In the subset of patients who received four consecutive capsaicin 8% patch treatments, the area of allodynia/hyperalgesia decreased from 227.4 cm² [268.5] (IQR: 51.5–282.5) before first treatment (n=80) to 213.4 cm² [254.4] (IQR: 43.0–299.0) before fourth treatment (n=84).

**Area of spontaneous pain**

The majority of patients reported painful areas at the torso (41.2%) or the feet (34.6%) before first treatment, and the distribution of painful areas remained similar throughout the study. In the total population, the mean [SD] area of maximal spontaneous pain decreased from 365.0 cm² [313.9] (IQR: 117.0–519.0) before first application to 322.7 cm² [324.2] (IQR: 82.0–472.0) at end of study. In patients with PHN (n=107), the area of pain decreased from 327.2 cm² [235.2] (IQR: 155.0–467.0) to 254.0 cm² [225.6] (IQR: 82.0–331.0).

In the subset of patients who received four consecutive capsaicin 8% patch treatments (n=100), the area of pain decreased from 310.1 cm² [275.4] (IQR: 97.5–437.5) to 268.5 cm² [254.4] (IQR: 74.5–409.5).

**Analgesic effectiveness**

**Average daily pain**

For the total population and each individual diagnostic group, a sustained reduction in average daily pain intensity was observed during the study (Figure 3a). The average daily pain [SD] was 6.6 [1.43] at baseline and 4.7 [2.27] at Month 12. The overall change in mean daily pain intensity was -1.9 [SD 1. 89; 95% CI: -2.19, -1.59] from baseline to Month 12. In patients with assessments at baseline and Month 12 (n=174), no differences in average daily pain reduction were observed between the total population and any of the individual diagnostic groups (data not shown).

In the subset of patients who received four consecutive capsaicin 8% patch treatments (n=100), a reduction in average daily pain was observed following each successive capsaicin treatment, and pain.
relief was sustained between treatments (Figure 3b). The change in average daily pain intensity was -2.1 [SD 1.7; 95% CI: -2.46, -1.78] from baseline to Month 12 in this subset of patients.

**Patient Global Impression of Change**

The majority of patients in the total population, as well as the individual diagnostic groups, reported an improvement in their overall status during the study. Of the total population, 31.6% of patients reported themselves to be ‘very much improved’ or ‘much improved’ by the end of the study (Figure 4). In patients who received four capsaicin 8% patch treatments (n=100), 48.1% reported themselves to be ‘very much improved’ or ‘much improved’ 4 weeks after their fourth treatment.

**Discussion**

The present study investigated for the first time the safety and tolerability of up to six capsaicin 8% patch treatments over 52 weeks in a large cohort of non-diabetic patients with various peripheral NP aetiologies. Of note, two thirds of patients received chronic pain medication, suggesting a relatively refractory pain condition. Results showed that capsaicin 8% patch repeat treatment over 52 weeks was well tolerated regardless of aetiology, with variable alteration in sensory function and a minimal risk of complete sensory loss. In addition, capsaicin 8% patch repeat treatment induced substantial and sustained reductions in pain over 52 weeks, with progressive reductions in line with the periods of each consecutive retreatment.

Methodological considerations of this study that are important to highlight include the study design and safety assessment. The study was designed so that patch application was dependent on the effectiveness and safety experienced by patients, reflecting use in routine clinical practice. Safety was assessed using a standardised neurological examination, which enabled qualitative categorisation of deficit and pain.

As capsaicin causes defunctionalisation of hyperactive nociceptors, which leads to pain relief, impaired sensory perception may have been a potential effect of the patch following repeat treatment. In addition,
regenerating small diameter fibres may be sensitive\textsuperscript{27} and can therefore lead to unwanted cutaneous
tenderness or frank pain. Indeed, both types of sensory changes were seen across all sensory modalities.
The development of new hyperalgesia/allodynia in a minority of patients may be considered an
unfortunate adverse effect, but it appears not to have had an effect on the total pain of these patients.
There was no substantial difference in pain scores or EQ-5D VAS scores in patients with worsened versus
improved sensory perception. In some patients there was a surprising change in large diameter fiber-
mediated sensory function (touch, vibration), the cause of which is not entirely clear. However,

improvement of such functions could lead to increased detection of applied stimuli. It is therefore
important to put these findings in clinical context and it is noteworthy that complete loss of sensation after
treatment was seen in only four patients. In one of these patients the patch was applied over the feet and
in the others it is was applied over the leg, torso and arm, where such sensory deterioration/loss would
have likely had less clinical effect. A total of 74 and 39 patients had sensory deterioration/loss in one and
two tests, respectively, while only 7 patients had sensory deterioration/loss in four tests. Sensory
deterioration in one or two tests is of limited clinical significance in this patient setting, and clinically may
be regarded as acceptable. In addition, following three consecutive treatments, no increase in sensory
deterioration was observed in patients, speaking against any cumulative sensory alteration at the
application site. In a recent exploratory study of 20 patients with peripheral NP, no significant
deterioration was shown in any sensory function other than warm detection following a single application
of the capsaicin 8\% patch\textsuperscript{28}. This result may seem to contradict findings of the present study; however,
sensory changes in the exploratory study were based on whole group analyses, whereas in the present
study the change in each sensory function in each individual was recorded. Given the main aim of safety
and the greater number of patch applications in the present study, we believe our method is better suited
to identify patients who might be particularly susceptible to adverse sensory effects of high concentration
capsaicin.
Although sensory deterioration/loss was reported by a proportion of patients, it is also noted that improvement in sensation was seen in 25.2–32.0% of treated patients by study end. Our putative hypothesis is that following capsaicin treatment, the phenotype of regenerated fibers may be closer to those unaffected by the disease, resulting in restoration of sensory perception; however, this hypothesis requires further study.

The secondary outcome of the present study concerned the analgesic effectiveness of repeated treatment with the capsaicin 8% patch. Repeated treatment with the capsaicin 8% patch induced a sustained reduction in average daily pain intensity for the total population, which similarly affected each individual diagnostic group and also the subgroup who received four consecutive capsaicin 8% patch treatments. The reduction in pain was consistent after each treatment, with no or minimal increase before retreatment. These results were supported by the global impression of improvement reported by about one-third of patients at the end of the study.

While the open-label design of this study may be considered more reflective of clinical practice, it is a major limitation, and as patients knew which treatment they were receiving, the findings related to analgesic effectiveness should be interpreted with caution. There was a high rate of patient discontinuation, which is consistent with the study design, but may also be considered a limitation. This was also a single-arm study, preventing comparison of results in patients who did not receive capsaicin. Regarding sensory testing, a single scale that only allowed the examiner to identify the most intense sensation may have masked other important sensory changes. Recovery of a patient with allodynia at baseline could have unmasked the presence of sensory deficit. The inherent inaccuracy in this methodology could have been avoided by using separate scales for sensory detection and suprathreshold stimuli, and further strengthened by application of quantitative sensory testing. Possible variation between investigators in the ‘bedside tests’ of sensory function and concomitant opioid use also need to be considered. The large number of centers involved was a major reason for the present choice of methodology, even if this may have compromised the accuracy of sensory assessment.
anaesthetics were used by all but one patient prior to capsaicin 8% patch treatment, with amides being the most common group. It is noted that lidocaine has been shown to have differential effects on sensory function. Detection thresholds were significantly elevated for touch, pinprick pain and mechanically induced wind-up after lidocaine 5% patch application in a randomised, double-blind study conducted in 20 healthy volunteers. However, this effect was completely reversed in 2–3 days, probably due to clearance of lidocaine from the skin. In the present study, sensory testing was performed several weeks after the previous application of the capsaicin 8% patch, making any impact from the use of topical anaesthetics on the results unlikely.

Conclusion
Capsaicin 8% patch repeat treatment over 52 weeks in various peripheral NP aetiologies was well tolerated, with mostly local adverse effects, resulted in variable sensory alteration, and no increase in area of allodynia or of maximum pain. Both improvement and worsening of sensation were observed with a minimal chance of complete sensory loss. No accumulation of any adverse effects was seen after three or four capsaicin 8% patch treatments. Sustained reductions in average pain intensity were also observed. The findings from this study demonstrate that capsaicin 8% patch repeat treatment is a well tolerated and effective long-term treatment option in patients with peripheral NP.

References


**Figure legends**

**Figure 1.** Patient flow during study

**Figure 2a.** Maximum number of treatments with capsaicin 8% patch (safety analysis set)

**Figure 2b.** Exposure to capsaicin 8% patch treatment (safety analysis set)
**Figure 3a.** Change from baseline in average daily pain throughout the study (safety analysis set)

**Figure 3b.** Change from baseline in average daily pain in patients who received four capsaicin 8% patch applications (post-hoc analysis)

**Figure 4.** Patient Global Impression of Change by end of the study (safety analysis set)

**Table 1.** Baseline demographics and characteristics (safety analysis set)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>PHN (n=107)</th>
<th>PNI (n=99)</th>
<th>HIV-DSPN (n=80)</th>
<th>Other peripheral NP (n=20)</th>
<th>Total (N=306)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>57 (53.3)</td>
<td>44 (44.4)</td>
<td>65 (81.3)</td>
<td>8 (40.0)</td>
<td>174 (56.9)</td>
</tr>
<tr>
<td><strong>Ethnicity, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>104 (97.2)</td>
<td>95 (96.0)</td>
<td>66 (82.5)</td>
<td>19 (95.0)</td>
<td>284 (92.8)</td>
</tr>
<tr>
<td>Black or African American</td>
<td>1 (0.9)</td>
<td>4 (4.0)</td>
<td>14 (17.5)</td>
<td>1 (5.0)</td>
<td>20 (6.5)</td>
</tr>
<tr>
<td>Asian</td>
<td>2 (1.9)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td><strong>Age, years [SD]</strong></td>
<td>70.5 [10.9]</td>
<td>49.7 [13.5]</td>
<td>51.5 [11.0]</td>
<td>56.5 [10.8]</td>
<td>57.9 [15.0]</td>
</tr>
<tr>
<td><strong>Time since pain diagnosis, years† [SD]</strong></td>
<td>3.9 [5.0]</td>
<td>4.0 [4.3]</td>
<td>7.4 [5.8]</td>
<td>7.7 [8.0]</td>
<td>5.1 [5.5]</td>
</tr>
<tr>
<td><strong>Pain interference index</strong> (BPI questions 9a to 9g)†† [SD]</td>
<td>4.4 [2.3]</td>
<td>5.5 [2.0]</td>
<td>5.4 [2.4]</td>
<td>5.1 [2.2]</td>
<td>5.1 [2.3]</td>
</tr>
<tr>
<td><strong>Least pain in last 24 h</strong></td>
<td>5.2 [2.3]</td>
<td>5.3 [2.2]</td>
<td>4.9 [2.2]</td>
<td>5.2 [1.8]</td>
<td>5.2 [2.2]</td>
</tr>
</tbody>
</table>

Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
(BPI question 4)†† [SD]

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Average pain in last 24 h (BPI question 5) [SD]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5, n (%)</td>
<td>17 (15.9)</td>
<td>6 (6.1)</td>
<td>13 (16.3)</td>
<td>1 (5.0)</td>
<td>37 (12.1)</td>
</tr>
<tr>
<td>≥5, n (%)</td>
<td>90 (84.1)</td>
<td>93 (93.9)</td>
<td>67 (83.8)</td>
<td>19 (95.0)</td>
<td>269 (87.9)</td>
</tr>
<tr>
<td>Prior pain medication, n (%)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analgesics</td>
<td>4 (3.7)</td>
<td>1 (1.0)</td>
<td>2 (2.5)</td>
<td>1 (5.0)</td>
<td>8 (2.6)</td>
</tr>
<tr>
<td>Antiepileptics</td>
<td>5 (4.7)</td>
<td>1 (1.0)</td>
<td>1 (1.3)</td>
<td>1 (5.0)</td>
<td>8 (2.6)</td>
</tr>
<tr>
<td>Anti-inflammatory and anti-rheumatics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 (1.9)</td>
<td>1 (1.0)</td>
<td>0</td>
<td>1 (5.0)</td>
<td>4 (1.3)</td>
</tr>
<tr>
<td>Topic joint/muscular pain products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 (1.9)</td>
<td>5 (5.1)</td>
<td>0</td>
<td>0</td>
<td>7 (2.3)</td>
</tr>
</tbody>
</table>

Data are mean [SD], unless otherwise indicated

†Time since diagnosis = (“date of baseline visit” – “date of diagnosis” + 1 day) / 365.25

†† Assessed at baseline in 278 patients (97 with PHN, 94 with PNI, 69 with HIV-DSPN, 18 with other peripheral NP)

*Used before baseline date, which was either ongoing at the time of baseline date or stopped prior to baseline date

NP, neuropathic pain
Table 2. Pain medication used by ≥5% of patients during the study (safety analysis set)

<table>
<thead>
<tr>
<th>Medication class, n (%)</th>
<th>PHN (n=107)</th>
<th>PNI (n=99)</th>
<th>HIV-DSPN (n=80)</th>
<th>Other peripheral NP (n=20)</th>
<th>Total (N=306)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>85 (79.4%)</td>
<td>83 (83.8%)</td>
<td>52 (65.0%)</td>
<td>18 (90.0%)</td>
<td>238 (77.8%)</td>
</tr>
<tr>
<td>Analgesics</td>
<td>77 (72.0%)</td>
<td>74 (74.7%)</td>
<td>41 (51.3%)</td>
<td>16 (80.0%)</td>
<td>208 (68.0%)</td>
</tr>
<tr>
<td>Other analgesics and antipyretics</td>
<td>60 (56.1%)</td>
<td>51 (51.5%)</td>
<td>29 (36.3%)</td>
<td>12 (60.0%)</td>
<td>152 (49.7%)</td>
</tr>
<tr>
<td>Anilides</td>
<td>32 (29.9%)</td>
<td>20 (20.2%)</td>
<td>11 (13.8%)</td>
<td>4 (20.0%)</td>
<td>67 (21.9%)</td>
</tr>
<tr>
<td>Other opioids</td>
<td>19 (17.8%)</td>
<td>28 (28.3%)</td>
<td>9 (11.2%)</td>
<td>4 (20.0%)</td>
<td>60 (19.6%)</td>
</tr>
<tr>
<td>Natural opium alkaloids</td>
<td>23 (21.5%)</td>
<td>21 (21.2%)</td>
<td>10 (12.5%)</td>
<td>3 (15.0%)</td>
<td>57 (18.6%)</td>
</tr>
<tr>
<td>Analgesics</td>
<td>9 (8.4%)</td>
<td>7 (7.1%)</td>
<td>3 (3.8%)</td>
<td>5 (25.0%)</td>
<td>24 (7.8%)</td>
</tr>
<tr>
<td>Antiepileptics</td>
<td>68 (63.6%)</td>
<td>55 (55.6%)</td>
<td>36 (45.0%)</td>
<td>14 (70.0%)</td>
<td>173 (56.5%)</td>
</tr>
<tr>
<td>Other antiepileptics</td>
<td>60 (56.1%)</td>
<td>51 (51.5%)</td>
<td>30 (37.5%)</td>
<td>13 (65.0%)</td>
<td>154 (50.3%)</td>
</tr>
<tr>
<td>Benzodiazepine derivatives</td>
<td>9 (8.4%)</td>
<td>7 (7.1%)</td>
<td>7 (8.8%)</td>
<td>3 (15.0%)</td>
<td>26 (8.5%)</td>
</tr>
<tr>
<td>Psychanaleptics</td>
<td>28 (26.2%)</td>
<td>29 (29.3%)</td>
<td>16 (20.0%)</td>
<td>12 (60.0%)</td>
<td>85 (27.8%)</td>
</tr>
<tr>
<td>Non-selective monoamine reuptake inhibitors</td>
<td>16 (15.0%)</td>
<td>22 (22.2%)</td>
<td>11 (13.8%)</td>
<td>7 (35.0%)</td>
<td>56 (18.3%)</td>
</tr>
<tr>
<td>Other antidepressants</td>
<td>12 (11.2%)</td>
<td>10 (10.1%)</td>
<td>3 (3.8%)</td>
<td>5 (25.0%)</td>
<td>30 (9.8%)</td>
</tr>
<tr>
<td>Urologicals</td>
<td>14 (13.1%)</td>
<td>11 (11.1%)</td>
<td>4 (5.0%)</td>
<td>5 (25.0%)</td>
<td>34 (11.1%)</td>
</tr>
<tr>
<td>Antinflammatory and antirheumatic products</td>
<td>7 (6.5%)</td>
<td>17 (17.2%)</td>
<td>5 (6.3%)</td>
<td>1 (5.0%)</td>
<td>30 (9.8%)</td>
</tr>
<tr>
<td>Topical products for joint and muscular pain†</td>
<td>7 (6.5%)</td>
<td>15 (15.2%)</td>
<td>6 (7.5%)</td>
<td>1 (5.0%)</td>
<td>29 (9.5%)</td>
</tr>
<tr>
<td>Cardiac therapy</td>
<td>12 (11.2%)</td>
<td>10 (10.1%)</td>
<td>4 (5.0%)</td>
<td>1 (5.0%)</td>
<td>27 (8.8%)</td>
</tr>
<tr>
<td>Other gynaecologicals*</td>
<td>5 (4.7%)</td>
<td>10 (10.1%)</td>
<td>3 (3.8%)</td>
<td>0 (0%)</td>
<td>18 (5.9%)</td>
</tr>
</tbody>
</table>
Treatments used for neuropathic pain, ongoing or starting on or after the baseline visit until end of study visit. A medication which could be classified into several therapeutic and/or chemical subgroups is presented in all therapeutic and chemical subgroups.

*Antiinflammatory products for vaginal administration
†Anti-inflammatory preparations and non-steroidals for topical use

HIV-DSPN, human immunodeficiency virus-associated distal sensory polyneuropathy; PHN, post-herpetic neuralgia; PNI, post-traumatic or post-surgical nerve injury nerve injury; NP, peripheral neuropathic pain

Table 3. Summary of treatment-related adverse events and drug-related treatment-related adverse events (safety analysis set)

<table>
<thead>
<tr>
<th>Event, n (%)</th>
<th>PHN (n=107)</th>
<th>PNI (n=99)</th>
<th>HIV-DSPN (n=80)</th>
<th>Other peripheral NP (n=20)</th>
<th>Total (N=306)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAEs</td>
<td>87 (81.3)</td>
<td>86 (86.9)</td>
<td>62 (77.5)</td>
<td>17 (85.0)</td>
<td>252 (82.4)</td>
</tr>
<tr>
<td>TEAEs identified as application site reactions</td>
<td>74 (69.2)</td>
<td>68 (68.7)</td>
<td>30 (37.5)</td>
<td>13 (65.0)</td>
<td>185 (60.5)</td>
</tr>
<tr>
<td>Most commonly reported TEAEs (≥5.0% of patients)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application site pain</td>
<td>46 (43.0)</td>
<td>40 (40.4)</td>
<td>21 (26.3)</td>
<td>5 (25.0)</td>
<td>112 (36.6)</td>
</tr>
<tr>
<td>Erythema</td>
<td>29 (27.1)</td>
<td>29 (29.3)</td>
<td>1 (1.3)</td>
<td>3 (15.0)</td>
<td>62 (20.3)</td>
</tr>
<tr>
<td>Application site erythema</td>
<td>24 (22.4)</td>
<td>19 (19.2)</td>
<td>2 (2.5)</td>
<td>6 (30.0)</td>
<td>51 (16.7)</td>
</tr>
<tr>
<td>Burning sensation</td>
<td>11 (10.3)</td>
<td>20 (20.2)</td>
<td>8 (10.0)</td>
<td>6 (30.0)</td>
<td>45 (14.7)</td>
</tr>
<tr>
<td>Pain</td>
<td>13 (12.1)</td>
<td>16 (16.2)</td>
<td>6 (7.5)</td>
<td>8 (40.0)</td>
<td>43 (14.1)</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>2 (1.9)</td>
<td>5 (5.1)</td>
<td>11 (13.8)</td>
<td>1 (5.0)</td>
<td>19 (6.2)</td>
</tr>
<tr>
<td>Nausea</td>
<td>4 (3.7)</td>
<td>8 (8.1)</td>
<td>1 (1.3)</td>
<td>3 (15.0)</td>
<td>16 (5.2)</td>
</tr>
<tr>
<td>TEAEs leading to treatment discontinuation</td>
<td>5 (4.7)</td>
<td>4 (4.0)</td>
<td>1 (1.3)</td>
<td>1 (5.0)</td>
<td>11 (3.6)</td>
</tr>
<tr>
<td>Drug-related TEAEs*</td>
<td>78 (72.9)</td>
<td>73 (73.7)</td>
<td>42 (52.5)</td>
<td>14 (70.0)</td>
<td>207 (67.6)</td>
</tr>
</tbody>
</table>

Most commonly reported drug-related TEAEs* (≥5.0% of patients)

| TEAE | 46 (43.0) | 40 (40.4) | 21 (26.3) | 5 (25.0) | 112 (36.6) |
| Application site pain | 29 (27.1) | 29 (29.3) | 1 (1.3) | 3 (15.0) | 62 (20.3) |
| Erythema | 24 (22.4) | 19 (19.2) | 2 (2.5) | 6 (30.0) | 51 (16.7) |
| Application site erythema | 11 (10.3) | 19 (19.2) | 8 (10.0) | 6 (30.0) | 44 (14.4) |
| Burning sensation | 7 (6.5) | 11 (11.1) | 4 (5.0) | 7 (35.0) | 29 (9.5) |

| TEAE | 1 (0.9) | 1 (1.0) | 0 (0) | 1 (5.0) | 3 (1.0) |
| Drug-related TEAEs* leading to treatment discontinuation | 23 (21.5) | 32 (32.3) | 19 (23.8) | 4 (20.0) | 78 (25.5) |
| Mild TEAEs† | 38 (35.5) | 31 (31.3) | 27 (33.8) | 8 (40.0) | 104 (34.0) |
| Moderate TEAEs† | 26 (24.3) | 23 (23.2) | 16 (20.0) | 5 (25.0) | 70 (22.9) |
| Severe TEAEs† | 14 (13.1) | 13 (13.1) | 8 (10.0) | 2 (10.0) | 37 (12.1) |
| Serious TEAEs | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Drug-related serious TEAEs* | 2 (1.9) | 0 (0.0) | 1 (1.3) | 0 (0.0) | 3 (1.0) |

*Possible or probable, as assessed by the investigator, or records where relationship is missing.
†Severity refers to maximum severity of TEAEs reported by patient.
‡‡All deaths were unrelated to capsaicin 8% patch treatment.

HIV-DSPN, human immunodeficiency virus-associated distal sensory polyneuropathy; NP, neuropathic pain; PHN, post-herpetic neuralgia; PNI, peripheral nerve injury; TEAEs, treatment-emergent adverse events
Table 4. Summary of sensory category shift changes from baseline to end of study (safety analysis set)

<table>
<thead>
<tr>
<th>Sensory shift, n (%)*</th>
<th>Pinprick (n=278)</th>
<th>Light brush (n=278)</th>
<th>Vibration (n=278)</th>
<th>Warm (n=277)</th>
<th>Cold (n=278)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensory deterioration/loss</td>
<td>45 (16.2)</td>
<td>41 (14.7)</td>
<td>50 (18.0)</td>
<td>54 (19.5)</td>
<td>58 (20.9)</td>
</tr>
<tr>
<td>New hyperaesthesia or allodynia</td>
<td>6 (2.2)</td>
<td>9 (3.2)</td>
<td>12 (4.3)</td>
<td>3 (1.1)</td>
<td>10 (3.6)</td>
</tr>
<tr>
<td>No change</td>
<td>130 (46.8)</td>
<td>137 (49.3)</td>
<td>113 (40.7)</td>
<td>121 (43.7)</td>
<td>130 (46.8)</td>
</tr>
<tr>
<td>Sensory improvement</td>
<td>70 (25.2)</td>
<td>73 (26.3)</td>
<td>89 (32.0)</td>
<td>86 (31.1)</td>
<td>71 (25.5)</td>
</tr>
<tr>
<td>Unclear change</td>
<td>27 (9.7)</td>
<td>18 (6.5)</td>
<td>14 (5.0)</td>
<td>13 (4.7)</td>
<td>9 (3.2)</td>
</tr>
</tbody>
</table>

*Definition of shift analyses shown in Supplementary Table 1.
The end of study (EoS) is the planned or early termination visit (9 weeks after last patch application) if available, otherwise the latest post-baseline assessment is used. Only those values of EoS that occurred after first patch application have been included into this analysis.
**Table 5.** Summary of sensory category shift changes following three consecutive capsaicin treatments

<table>
<thead>
<tr>
<th>Sensory shift, n (%)*</th>
<th>Pinprick (n=100)</th>
<th>Light brush (n=100)</th>
<th>Vibration (n=100)</th>
<th>Warm (n=99)</th>
<th>Cold (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensory deterioration/loss</td>
<td>14 (14.0)</td>
<td>20 (20.0)</td>
<td>17 (17.0)</td>
<td>19 (19.2)</td>
<td>20 (20.0)</td>
</tr>
<tr>
<td>New hyperaesthesia or alldynia</td>
<td>1 (1.0)</td>
<td>4 (4.0)</td>
<td>2 (2.0)</td>
<td>1 (1.0)</td>
<td>4 (4.0)</td>
</tr>
<tr>
<td>No change</td>
<td>48 (48.0)</td>
<td>44 (44.0)</td>
<td>39 (39.0)</td>
<td>41 (41.4)</td>
<td>41 (41.0)</td>
</tr>
<tr>
<td>Sensory improvement</td>
<td>26 (26.0)</td>
<td>28 (28.0)</td>
<td>37 (37.0)</td>
<td>32 (32.3)</td>
<td>31 (31.0)</td>
</tr>
<tr>
<td>Unclear change</td>
<td>11 (11.0)</td>
<td>4 (4.0)</td>
<td>5 (5.0)</td>
<td>6 (6.1)</td>
<td>4 (4.0)</td>
</tr>
</tbody>
</table>

*Definition of shift analyses shown in Supplementary Table 1.
Figure 1. Patient flow during study

- Screened (n=345)
  - Screening failures (n=39)
  - Treated (n=306)
    - PHN (n=107)
      - SAF (n=107)
        - Discontinued (n=41)
          - Reason:
            - Lack of efficacy (n=16)
            - Withdrawal of consent (n=11)
            - Adverse event (n=5)
            - Subject lost to follow-up (n=5)
            - Protocol violation (n=3)
            - Other (n=1)
        - Completed study (n=66)
    - HIV-DSPN (n=80)
      - SAF (n=80)
        - Discontinued (n=35)
          - Reason:
            - Withdrawal of consent (n=13)
            - Lack of efficacy (n=8)
            - Subject lost to follow-up (n=6)
            - Other (n=5)
            - Protocol violation (n=2)
            - Adverse event (n=1)
        - Completed study (n=45)
    - PNI (n=99)
      - SAF (n=99)
        - Discontinued (n=45)
          - Reason:
            - Lack of efficacy (n=24)
            - Withdrawal of consent (n=8)
            - Subject lost to follow-up (n=6)
            - Adverse event (n=4)
            - Other (n=2)
            - Protocol violation (n=1)
        - Completed study (n=54)
    - Other peripheral NP (n=20)
      - SAF (n=20)
        - Discontinued (n=9)
          - Reason:
            - Lack of efficacy (n=6)
            - Adverse event (n=1)
            - Other (n=1)
            - Withdrawal of consent (n=1)
        - Completed study (n=11)

HIV-DSPN, human immunodeficiency virus-associated distal sensory polyneuropathy; NP, neuropathic pain; PHN, postherpetic neuralgia; PNI, post-traumatic or post-surgical nerve injury; SAS, safety analysis set.
Figure 2a. Maximum number of treatments with capsaicin 8% patch (safety analysis set)

HIV-DSPN, HIV-associated distal sensory polyneuropathy; PHN, post-herpetic neuralgia; PNI, post-traumatic or post-surgical nerve injury; NP, neuropathic pain

Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Figure 2b. Exposure to capsaicin 8% patch treatment (safety analysis set)

- Total population (N=306)
- PHN (n=107)
- PNI (n=99)
- HIV-DSPN (n=80)
- Other peripheral NP (n=20)

HIV-DSPN, HIV-associated distal sensory polyneuropathy; PHN, post-herpetic neuralgia; PNI, post-traumatic or post-surgical nerve injury; NP, neuropathic pain
Figure 3a. Change from baseline in average daily pain throughout the study (safety analysis set)

Arrows show the average day of successive capsaicin treatments and number of patients receiving treatment: second treatment, 98.9 days after first (Day 99); third treatment, 109.5 days after second (Day 208); fourth treatment, 99.3 days after third (Day 308). Time estimated for second, third and fourth treatments.

HIV-DSPN, HIV-associated distal sensory polyneuropathy; PHN, post-herpetic neuralgia; PNI, post-traumatic or post-surgical nerve injury; NP, neuropathic pain

Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Figure 3b. Change from baseline in average daily pain in patients who received four capsaicin 8% patch applications (post-hoc analysis)
Figure 4. Patient Global Impression of Change by end of the study (safety analysis set)

This figure shows the 'very much improved' and 'much improved' categories twice to illustrate the difference between those patients who were at least much improved versus those with any degree of improvement; n is number of patients with non-missing data.

HIV-DSPN, HIV-associated distal sensory polyneuropathy; PHN, post-herpetic neuralgia; PNI, post-traumatic or post-surgical nerve injury; NP, neuropathic pain.